Atish D. Choudhury, MD, PhD, discusses the significance of optimizing patient selection when using PARP inhibitors for prostate cancer. Using these agents in patients unlikely to benefit adds unnecessary pill, toxicity, and financial burdens to the recipient, explains Choudhury. He notes the importance of finding biomarkers to facilitate appropriate patient selection.
Choudhury is a medical oncologist and clinical/translational investigator within the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, and currently serves as Chair of the Gelb Center for Translational Research.
Cell-cycle risk score is predictive of ADT benefit in prostate cancer
May 17th 2024"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.